Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.22.2.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

    

Three-Month Periods Ended

    

Nine-Month Periods Ended

September 30, 

September 30, 

($ in thousands)

    

2022

    

2021

    

2022

    

2021

Qbrexza®

$

6,265

$

6,636

$

19,752

$

11,204

Accutane®

 

4,121

 

3,531

 

14,228

 

5,672

Amzeeq

1,161

5,892

Targadox®

1,168

5,184

6,558

18,110

Ximino®

1,773

2,864

3,775

6,277

Zilxi

554

1,851

Exelderm®

 

1,001

 

1,366

 

3,018

 

4,319

Other branded revenue

 

 

29

 

 

35

Total product revenues

$

16,043

$

19,610

$

55,074

$

45,617

Schedule of other revenue

    

Three-Month Periods Ended

 

Nine-Month Periods Ended

September 30, 

 

September 30, 

($ in thousands)

    

2022

    

2021

    

2022

    

2021

Other revenue

 

73

 

2,629

 

Total other revenue

$

73

$

$

2,629

$